CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.

导出 LinkOut

翻译打印收藏纠错

作者： Caspian,Oliai ^[1] ; Sunmin,Park ^[1] ; Lloyd E,Damon ^[2] ; Brian A,Jonas ^[3] ; Deepa,Jeyakumar ^[4] ; Matthew J,Wieduwilt ^[5] ; Aaron C,Logan ^[2] ; Bradley,Callas ^[1] ; Chris A,Hannigan ^[1] ; Daria L,Gaut ^[1] ; Gary J,Schiller ^[1]

作者单位： Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA. ^[1] Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA. ^[2] Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, CA, USA. ^[3] Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, School of Medicine, Orange, CA, USA. ^[4] Department of Internal Medicine, Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. ^[5]

关键词 AML CPX-351 gemtuzumab ozogamicin

DOI 10.1080/10428194.2024.2438809

PMID 39689718

发布时间 2025-01-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia & lymphoma

1-7页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.

Leukemia & lymphoma

相似文献

Leukemia & lymphoma

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.

Leukemia & lymphoma

相似文献

Leukemia & lymphoma

相关期刊

检索历史清除